phrykt

SOPHiA GENETICS SA (SOPH): who owns it and who trades it

As of Nov 16, 2026, SOPH insiders reported 146 open-market sales worth $5.2M and 3 purchases worth $377K in the last 12 months, with 99% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jurgi Camblong (CEO), with $2.8M. 6 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Sophia Genetics Sa

From the latest filings

Overall: more buying than selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns SOPH

72 funds and institutions reported SOPH shares worth $213M at the end of Q2 2026, about 54% of the company. The largest holder is Generation Investment Management LLP with 9.9%.

Funds and institutions (13F) 54%Everyone else 46%

10 largest owners, by share of the company

Generation Investment Management LLP9.9%
AIGH Capital Management LLC5.8%
Akre Capital Management LLC5.4%
Royce & Associates LP4.9%
Principal Financial Group Inc3.5%
Ameriprise Financial Inc3.2%
Banque Pictet & Cie SA3.2%
AWM Investment Company, Inc.2.5%
Soleus Capital Management, L.P.2.3%
Silvercrest Asset Management Group LLC2.1%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Generation Investment Management LLP6.79M9.91%$39.2MNo change
AIGH Capital Management LLC3.95M5.77%$22.8MNew
Akre Capital Management LLC3.72M5.43%$21.5MNo change
Royce & Associates LP3.38M4.94%$19.5M+86%
Principal Financial Group Inc2.36M3.45%$13.6M+68%
Ameriprise Financial Inc2.22M3.24%$12.8MNew
Banque Pictet & Cie SA2.21M3.22%$12.7MNo change
AWM Investment Company, Inc.1.70M2.48%$9.8MNew
Soleus Capital Management, L.P.1.56M2.29%$9M-15%
Silvercrest Asset Management Group LLC1.43M2.09%$8.2MNew
Alta Wealth Advisors LLC1.41M2.06%$8.1MNo change
Kennedy Capital Management LLC917,9771.34%$5.3M-1%
Archon Capital Management LLC691,4131.01%$4M+57%
Essex Investment Management Co LLC663,4280.97%$3.8M-4%
Ensign Peak Advisors, Inc444,6540.65%$2.6M-0%
Hodges Capital Management Inc.409,0730.60%$2.4M-6%
Bank Pictet & Cie (Europe) AG255,2000.37%$1.5MNo change
Legato Capital Management LLC223,2300.33%$1.3M+3%
1492 Capital Management LLC222,1940.32%$1.3M-2%
Edmond DE Rothschild Holding S.a.200,0040.29%$1.2M-2%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, SOPH insiders reported $377K of open-market purchases and $5.2M of sales. 99% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$377K
3 trades, 2 people
Sales, 12 months
$5.2M
146 trades, 10 people
Sales under a 10b5-1 plan
99%
Share of sale value
Latest trade
Nov 13, 2026
Filed Nov 16, 2026

Purchases and sales by month

$1.1M$1.1MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 13, 2026Zhenyu XuChief Scientific OfficerSale plan4,000$7.96$31.8KForm 4
Nov 12, 2026Philippe MenuChief Medical OfficerSale plan5,000$7.68$38.4KForm 4
Nov 10, 2026Jurgi CamblongChairSale plan8,500$7.76$65.9KForm 4
Nov 10, 2026Kathy L HibbsDirectorSale plan6,250$7.76$48.5KForm 4
Nov 9, 2026Well Daan VanChief Legal OfficerSale plan1,411$7.44$10.5KForm 4
Nov 6, 2026George CardozaCFOPurchase20,000$7.06$141KForm 4
Nov 6, 2026Ross MukenCEOPurchase20,000$6.86$137KForm 4
Oct 13, 2026Zhenyu XuChief Scientific OfficerSale plan4,000$7.18$28.7KForm 4
Oct 12, 2026Jurgi CamblongChairSale plan8,500$7.26$61.7KForm 4
Oct 12, 2026Philippe MenuChief Medical OfficerSale plan5,000$7.26$36.3KForm 4
Oct 5, 2026George CardozaCFOSale plan1,592$8.10$12.9KForm 4
Oct 5, 2026Jurgi CamblongChairSale plan40,172$8.13$327KForm 4
Oct 5, 2026Philippe MenuChief Medical OfficerSale plan7,394$8.13$60.1KForm 4
Oct 5, 2026Ross MukenCEOSale plan9,838$8.13$80KForm 4
Oct 5, 2026Kevin PuylaertChief Sales OfficerSale185$8.06$1.5KForm 4
Oct 5, 2026Kevin PuylaertChief Sales OfficerSale31$7.92$246Form 4
Oct 5, 2026Zhenyu XuChief Scientific OfficerSale plan7,394$8.12$60.1KForm 4
Oct 5, 2026Abhimanyu VermaChief Technology OfficerSale plan5,284$8.12$42.9KForm 4
Oct 5, 2026Manuela ValenteChief People OfficerSale plan4,240$8.13$34.5KForm 4
Oct 5, 2026Well Daan VanChief Legal OfficerSale plan6,168$8.12$50.1KForm 4
Sep 21, 2026George CardozaCFOSale plan774$8.33$6.4KForm 4
Sep 21, 2026Ross MukenCEOSale plan422$8.33$3.5KForm 4
Sep 14, 2026Philippe MenuChief Medical OfficerSale5,000$7.88$39.4KForm 4
Sep 14, 2026Zhenyu XuChief Scientific OfficerSale plan4,000$7.88$31.5KForm 4
Sep 11, 2026Well Daan VanChief Legal OfficerSale plan6,168$7.63$47.1KForm 4
Sep 10, 2026Jurgi CamblongChairSale plan8,500$7.66$65.1KForm 4
Sep 8, 2026Kathy L HibbsDirectorSale plan6,250$8.13$50.8KForm 4
Aug 27, 2026Zhenyu XuChief Scientific OfficerSale plan10,000$8.91$89.1KForm 4
Aug 25, 2026Philippe MenuChief Medical OfficerSale plan5,000$8.68$43.4KForm 4
Aug 25, 2026Kathy L HibbsDirectorSale plan6,250$8.68$54.2KForm 4
Aug 24, 2026Abhimanyu VermaChief Technology OfficerSale plan5,000$8.80$44KForm 4
Aug 21, 2026Zhenyu XuChief Scientific OfficerSale plan5,408$8.40$45.4KForm 4
Aug 20, 2026Zhenyu XuChief Scientific OfficerSale plan4,592$8.41$38.6KForm 4
Aug 19, 2026Abhimanyu VermaChief Technology OfficerSale plan5,000$8.20$41KForm 4
Aug 19, 2026Manuela ValenteChief People OfficerSale plan10,000$7.94$79.4KForm 4
Aug 13, 2026Zhenyu XuChief Scientific OfficerSale plan4,000$7.52$30.1KForm 4
Aug 12, 2026Philippe MenuChief Medical OfficerSale plan5,000$7.52$37.6KForm 4
Aug 10, 2026Jurgi CamblongChairSale plan8,500$7.61$64.7KForm 4
Aug 7, 2026Abhimanyu VermaChief Technology OfficerSale plan5,000$7.60$38KForm 4
Aug 7, 2026Jurgi CamblongChairSale plan20,000$7.23$145KForm 4
Aug 7, 2026Zhenyu XuChief Scientific OfficerSale plan10,000$7.48$74.8KForm 4
Aug 7, 2026Zhenyu XuChief Scientific OfficerSale plan7,000$7.02$49.1KForm 4
Aug 5, 2026Zhenyu XuChief Scientific OfficerSale plan3,000$7.00$21KForm 4
Aug 4, 2026Abhimanyu VermaChief Technology OfficerSale plan5,000$6.95$34.8KForm 4
Aug 4, 2026Jurgi CamblongChairSale plan20,000$6.92$138KForm 4
Aug 4, 2026Zhenyu XuChief Scientific OfficerSale plan10,000$6.92$69.2KForm 4
Jul 27, 2026Philippe MenuChief Medical OfficerSale plan5,000$5.66$28.3KForm 4
Jul 21, 2026Jurgi CamblongChairSale plan20,000$6.63$133KForm 4
Jul 20, 2026Jurgi CamblongChairSale plan19,800$6.32$125KForm 4
Jul 20, 2026Jurgi CamblongChairSale plan4,581$6.17$28.3KForm 4
Jul 13, 2026Philippe MenuChief Medical OfficerSale plan5,000$5.70$28.5KForm 4
Jul 13, 2026Zhenyu XuChief Scientific OfficerSale plan4,000$5.70$22.8KForm 4
Jul 10, 2026Jurgi CamblongChairSale plan8,500$5.62$47.8KForm 4
Jul 7, 2026Jurgi CamblongChairSale plan17,685$5.28$93.4KForm 4
Jul 6, 2026George CardozaCFOSale plan1,592$5.29$8.4KForm 4
Jul 6, 2026Manuela ValenteChief People OfficerSale plan4,241$5.05$21.4KForm 4
Jul 6, 2026Abhimanyu VermaChief Technology OfficerSale plan5,285$5.10$27KForm 4
Jul 6, 2026Zhenyu XuChief Scientific OfficerSale plan7,393$5.17$38.2KForm 4
Jul 6, 2026Ross MukenCEOSale plan9,838$5.22$51.4KForm 4
Jul 6, 2026Kevin PuylaertChief Sales OfficerSale47$5.03$236Form 4
Jul 6, 2026Kevin PuylaertChief Sales OfficerSale138$5.03$694Form 4
Jul 6, 2026Kevin PuylaertChief Sales OfficerSale31$5.09$158Form 4
Jul 6, 2026Philippe MenuChief Medical OfficerSale plan7,393$5.16$38.1KForm 4
Jul 6, 2026Jurgi CamblongChairSale plan22,486$5.26$118KForm 4
Jun 30, 2026Jurgi CamblongChairSale plan200$6.30$1.3KForm 4
Jun 30, 2026Jurgi CamblongChairSale plan19,650$6.02$118KForm 4
Jun 30, 2026Jurgi CamblongChairSale plan45,419$6.14$279KForm 4
Jun 29, 2026Jurgi CamblongChairSale plan350$6.00$2.1KForm 4
Jun 29, 2026Jurgi CamblongChairSale plan18,060$5.87$106KForm 4
Jun 26, 2026Jurgi CamblongCEOSale plan31,940$5.84$187KForm 4
Jun 26, 2026Jurgi CamblongCEOSale plan18,129$5.73$104KForm 4
Jun 25, 2026Jurgi CamblongCEOSale plan1,373$5.70$7.8KForm 4
Jun 25, 2026Abhimanyu VermaChief Technology OfficerSale plan6,944$5.51$38.3KForm 4
Jun 25, 2026Philippe MenuChief Medical OfficerSale plan5,000$5.50$27.5KForm 4
Jun 22, 2026George CardozaCFOSale plan774$5.38$4.2KForm 4
Jun 22, 2026Ross MukenPresidentSale plan422$5.38$2.3KForm 4
Jun 15, 2026Zhenyu XuChief Scientific OfficerSale plan4,000$5.01$20KForm 4
Jun 12, 2026Philippe MenuChief Medical OfficerSale plan5,000$4.95$24.8KForm 4
Jun 10, 2026Jurgi CamblongCEOSale plan8,500$5.24$44.5KForm 4
Jun 5, 2026George CardozaCFOPurchase20,000$4.95$99KForm 4
May 26, 2026Philippe MenuChief Medical OfficerSale plan5,000$4.95$24.8KForm 4
May 19, 2026Ross MukenPresidentSale plan761$4.60$3.5KForm 4
May 19, 2026Zhenyu XuChief Scientific OfficerSale plan608$4.60$2.8KForm 4
May 19, 2026Jurgi CamblongCEOSale plan4,486$4.60$20.6KForm 4
May 19, 2026Philippe MenuChief Medical OfficerSale plan608$4.61$2.8KForm 4
May 19, 2026Well Daan VanChief Legal OfficerSale plan684$4.60$3.1KForm 4
May 19, 2026Manuela ValenteChief People OfficerSale plan380$4.60$1.7KForm 4
May 19, 2026Kevin PuylaertChief Sales OfficerSale33$4.54$150Form 4
May 13, 2026Zhenyu XuChief Scientific OfficerSale plan4,000$4.54$18.2KForm 4
May 12, 2026Kathy L HibbsDirectorSale plan7,508$4.67$35.1KForm 4
May 12, 2026Philippe MenuChief Medical OfficerSale plan5,000$4.67$23.4KForm 4
May 11, 2026Jurgi CamblongCEOSale plan8,500$5.09$43.3KForm 4
Apr 27, 2026Philippe MenuChief Medical OfficerSale plan5,000$4.82$24.1KForm 4
Apr 20, 2026Manuela ValenteChief People OfficerSale plan380$5.20$2KForm 4
Apr 20, 2026Zhenyu XuChief Scientific OfficerSale plan608$5.21$3.2KForm 4
Apr 20, 2026Well Daan VanChief Legal OfficerSale plan684$5.20$3.6KForm 4
Apr 20, 2026Jurgi CamblongCEOSale plan4,486$5.21$23.4KForm 4
Apr 20, 2026Philippe MenuChief Medical OfficerSale plan608$5.20$3.2KForm 4
Apr 20, 2026Ross MukenPresidentSale plan760$5.20$4KForm 4
Apr 20, 2026Kevin PuylaertChief Sales OfficerSale33$5.08$168Form 4

Latest 100 of 149 trades in the last 12 months.

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Jurgi CamblongChief Executive Officer, Director–$2.8MNov 10, 2026
Zhenyu XuChief Scientific Officer–$728KNov 13, 2026
Philippe MenuChief Medical Officer–$548KNov 12, 2026
Ross MukenPresident$137K$240KNov 6, 2026
George CardozaChief Financial Officer$240K$66.4KNov 6, 2026
Abhimanyu VermaChief Technology Officer–$283KOct 5, 2026
Kathy L HibbsDirector–$189KNov 10, 2026
Manuela ValenteChief People Officer–$184KOct 5, 2026
Well Daan VanChief Legal Officer–$165KNov 9, 2026
Kevin PuylaertChief Sales Officer–$6.3KOct 5, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

SOPH short interest

1.15M SOPH shares are sold short. Over the last 12 reports the number of shares short went up 389%.

As of Oct 30, 2026, 1.15M SOPH shares were sold short, up 14.8% from the report before. At the average daily volume of 438,231 shares, buying them all back would take about 2.6 trading days (days to cover).

Shares short, % of all shares

0.97%May 15Jul 151.06%

Days to cover

2.6May 15Oct 304.7

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20261.15M–+15%438,2312.6
Oct 15, 20261.00M–-11%691,9081.4
Sep 30, 20261.12M–+5%653,8691.7
Sep 15, 20261.07M–-3%638,8801.7
Aug 31, 20261.10M–+19%575,5001.9
Aug 14, 2026930,712–+21%557,8291.7
Jul 31, 2026768,289–+16%290,1982.6
Jul 15, 2026661,3520.97%+4%313,7922.1
Jun 30, 2026636,1320.93%+141%459,3291.4
Jun 15, 2026263,6010.38%-6%140,9411.9
May 29, 2026279,1030.41%+19%64,9104.3
May 15, 2026234,7410.34%+18%119,0462.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Famous investors that hold SOPH

6 of the 50 well-known investors we track reported holding SOPH in their latest 13F filing. The largest position is Chuck Akre's, worth $31.2M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Chuck Akre · Akre Capital ManagementQ3 20263.72M$31.2M0.7%No change
Steve Cohen · Point72 Asset ManagementQ3 20261.57M$13.1M0.0%New
Ken Griffin · Citadel AdvisorsQ3 2026746,052$6.3M0.0%+1838%
Jim Simons · Renaissance TechnologiesQ3 2026270,900$2.3M0.0%+139%
Israel Englander · Millennium ManagementQ3 2026214,308$1.8M0.0%+55%
Paul Tudor Jones · Tudor Investment CorpQ3 2026152,886$1.3M0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named SOPH in the last 120 days.

FiledHolderFormStake
Nov 12, 2026Schindel Yair Chaim13D/A6.2%
Nov 12, 2026Schindel Yair Chaim13D/A6.2%

Questions about SOPHiA GENETICS SA (SOPH) stock

Who owns the most SOPH stock?

The largest reported owner of SOPHiA GENETICS SA (SOPH) is Generation Investment Management LLP, with 9.9% of the company. In total, 72 funds and institutions reported holding SOPH at the end of Q2 2026, together about 54% of the shares. See the largest owners.

Are SOPH insiders buying or selling?

In the last 12 months, SOPH insiders reported 3 open-market purchases worth $377K and 146 sales worth $5.2M. The latest trade was on Nov 13, 2026. See every trade.

What is the short interest in SOPH?

As of Oct 30, 2026, 1.15M SOPH shares were sold short, up 14.8% from the report before. At the average daily volume of 438,231 shares, buying them all back would take about 2.6 trading days (days to cover). See the history.

Which famous investors hold SOPH?

6 of the 50 well-known investors we track reported SOPH in their latest 13F filing, including Chuck Akre, Steve Cohen, Ken Griffin. The largest position is worth $31.2M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.